c3b46d4b-4d9f-4d2d-bbca-c0dbd6901e56
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.500
- WNT_BETA_CATENIN_SIGNALING+0.500
- MYC_TARGETS_V2+0.300
- APICAL_JUNCTION+0.200
- APICAL_SURFACE+0.200
- KRAS_SIGNALING_DN+0.200
- MYOGENESIS+0.200
- CHOLESTEROL_HOMEOSTASIS+0.100
- COAGULATION+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- INTERFERON_GAMMA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- ANDROGEN_RESPONSE-0.300
- COMPLEMENT-0.300
- E2F_TARGETS-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 8683d8f5-bba5-40a1-a460-ad6183d2302b | — | — | 0.851 |
| 2 | 38aa467f-bd67-475e-9280-7e710bdc0cb3 | — | — | 0.825 |
| 3 | f17e12f0-54ed-4dc2-ab7e-22a1f90e1405 | — | — | 0.824 |
| 4 | C3L-02163 | — | cohortSQ2 | 0.822 |
| 5 | SRR17866827 | — | — | 0.799 |
| 6 | 4e24bc58-d246-4c96-952a-a18f95d142b2 | — | — | 0.795 |
| 7 | MNG857 | — | — | 0.789 |
| 8 | SRR17866843 | — | — | 0.787 |
| 9 | 701e70ac-31d2-4e78-95e1-3fa2bb466e83 | — | — | 0.787 |
| 10 | R98 | — | — | 0.787 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.500 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.100 | Inavolisib | — uncovered |